Hence, in 2016 the World Health Organization (WHO) incorporated isocitrate dehydrogenase (IDH) gene mutations and 1p/19q codeletion as essential biomarkers to adequately stratify gliomas, while also refining the previously established histological criteria [13]. This evidence concerns the gene IDH1 and central nervous system cancer.